OMB APPROVAL

                                                       OMB Number 3235-0145
                                                       Expires: October 31, 2002
                                                       Estimated average burden
                                                       hours per response...14.9

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                  SCHEDULE 13D

                    UNDER THE SECURITIES EXCHANGE ACT OF 1934
                                (AMENDMENT NO. 9)

                                  ALPHARMA INC.
                                (Name of Issuer)

                 CLASS A COMMON STOCK, PAR VALUE $.20 PER SHARE
                         (Title of Class of Securities)

                                   001629 10 4
                                 (CUSIP Number)

                                EINAR W. SISSENER
                                C/O ALPHARMA INC.
                               ONE EXECUTIVE DRIVE
                           FORT LEE, NEW JERSEY 07024

                  (Name, Address and Telephone Number of Person
                Authorized to Receive Notices and Communications)


                               SEPTEMBER 30, 2002
             (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g),
check the following box. [ ]

NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Section 240.13d-7 for other
parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).


                                Page 1 of 6 Pages

----------------------                                         ----------------
CUSIP No. 001629 10 4                   13D                    Page 2 of 6
                                                               Pages
----------------------                                         ----------------



   1    NAMES OF REPORTING PERSONS / I.R.S. IDENTIFICATION NOS. OF ABOVE
        PERSONS
        (ENTITIES ONLY)

              A. L. Industrier ASA

   2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                                     (a) [ ]
                                                                     (b) [ ]
   3    SEC USE ONLY

   4    SOURCE OF FUNDS*

              00, BK

   5    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
        PURSUANT TO ITEMS 2(D) OR 2(E)                                   [ ]

   6    CITIZENSHIP OR PLACE OF ORGANIZATION

              Norway

                            7    SOLE VOTING POWER

        NUMBER OF                      11,872,897
         SHARES
      BENEFICIALLY          8    SHARED VOTING POWER

        OWNED BY                       -0-

          EACH              9    SOLE DISPOSITIVE POWER
        REPORTING
                                       11,872,897
         PERSON
          WITH              10   SHARED DISPOSITIVE POWER

                                       -0-

  11    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

              11,872,897

  12    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
        SHARES*                                                          [ ]

  13    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

              23.16%

  14    TYPE OF REPORTING PERSON*

              CO

* SEE INSTRUCTIONS.

                  AMENDMENT NO. 9 TO STATEMENT ON SCHEDULE 13D

      Pursuant to Rule 13d-2(a) of Regulation 13D-G of the General Rules and
Regulations under the Securities Exchange Act of 1934, as amended (the "Act"),
the undersigned ("Industrier") hereby files this Amendment No. 9 to its Schedule
13D Statement dated February 19, 1997 (as amended from time to time, the
"Schedule 13D") relating to the Class A Common Stock, par value $.20 per share
(the "Common Stock") of Alpharma Inc. (the "Issuer") to amend the items and
schedules set forth herein and to file an exhibit. No amendment is made to the
items or schedules not set forth below. Capitalized terms used but not otherwise
defined herein have the meanings set forth in the Schedule 13D.

      ITEM 3.  SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

      As disclosed in the Schedule 13D and previous amendments thereto,
Industrier has used funds borrowed from Den norske Bank ASA (the "Bank") to
purchase securities of the Issuer. Pursuant to the loan agreement dated August
13, 2001 by and between the Bank and AL Chemy AS ("AL Chemy"), filed as Exhibit
1 to Amendment No. 6 to the Schedule 13D (the "AL Chemy Loan Agreement"), the
Bank provided AL Chemy with a loan of $100,000,000, of which approximately
$22,000,000 remains outstanding. On August 12, 2002, the Bank provided a letter
to Industrier and AL Chemy, filed as Exhibit 1 to Amendment No. 7 to the
Schedule 13D, in which, among other things, the Bank agreed to extend the term
of the AL Chemy Loan Agreement until September 15, 2002 and to modify the
default provisions to require the maintenance of certain collateral value (which
includes a computation based, in part, on the market value of the Common Stock).
The remaining default provisions are as set forth in Section 13.1 of the AL
Chemy Loan Agreement filed as Exhibit 1 to Amendment No. 6 to the Schedule 13D,
the provisions of which are incorporated herein by reference. The terms of this
letter were extended until October 1, 2002 pursuant to a letter provided to
Industrier and AL Chemy, filed as Exhibit 1 to Amendment No. 8 to the Schedule
13D, by the Bank.

      On September 30, 2002, the Bank provided a letter to Industrier and AL
Chemy, filed as Exhibit 1 to this Amendment No. 9 to the Schedule 13D and
incorporated herein by reference, in which the Bank agreed to further extend the
term of the AL Chemy Loan Agreement until November 1, 2002 and to extend the
modifications of the default provisions described in the above paragraph. In the
aforementioned letter, the Bank also acknowledged that the parties are
negotiating a further extension to the AL Chemy Loan Agreement which would
include certain modifications of its terms.

      The information set forth in Items 4 and 5 of this Schedule 13D is hereby
incorporated herein by reference.

      ITEM 4.  PURPOSE OF TRANSACTION.

      The purpose of the transaction described in Item 3 above was to extend and
modify the AL Chemy Loan Agreement.

      Subject to such actions as may be taken pursuant to the Issuer's Board of
Directors in the normal course of carrying out its responsibilities (including
pursuing a corporate strategy which includes seeking the acquisition of other
businesses), Industrier has no plan or proposal that relates to or would result
in:

      (a)   The acquisition by any person of additional securities of the
            Issuer, or the disposition of securities of the Issuer;

      (b)   An extraordinary corporate transaction, such as a merger,
            reorganization or liquidation, involving the Issuer or any of its
            subsidiaries;


                               Page 3 of 6 Pages

      (c)   A sale or transfer of a material amount of assets of the Issuer or
            any of its subsidiaries;

      (d)   Any change in the present board of directors (except as may occur at
            the next annual meeting of the Issuer) or management of the Issuer,
            including any plans or proposals to change the number or term of
            directors or to fill any existing vacancies on the board;

      (e)   Any material change in the present capitalization or dividend policy
            of the Issuer;

      (f)   Any other material change in the Issuer's business or corporate
            structure;

      (g)   Changes in the Issuer's charter, bylaws or instruments corresponding
            thereto or other actions which may impede the acquisition of control
            of the Issuer by any person;

      (h)   Causing a class of securities of the Issuer to be delisted from a
            national securities exchange or to cease to be authorized to be
            quoted in an inter-dealer quotation system of a registered national
            securities association;

      (i)   A class of equity securities of the Issuer becoming eligible for
            termination of registration pursuant to Section 12(g)(4) of the Act;
            or

      (j)   Any action similar to any of those enumerated above.

Nothing herein is intended to limit Industrier's right and ability to suggest to
the Issuer a plan or proposal for any such action in the future and to exercise
its voting rights in its discretion as holder of the Class B Stock of the Issuer
to elect a majority of the Issuer's directors.

      The information set forth in Item 3 of this Schedule 13D is hereby
incorporated herein by reference.

      ITEM 5.  INTEREST IN SECURITIES OF THE ISSUER.

      (a)   Industrier beneficially owns 11,872,897 shares of Common Stock which
            it may acquire upon conversion, on a share for share basis, of the
            Class B Stock which it beneficially owns. Such beneficial ownership
            constitutes approximately 23.16% of the outstanding Common Stock
            (assuming conversion of the Class B Stock and the issuance of no
            shares of Common Stock pursuant to any outstanding options or
            convertible securities of the Issuer).

            Pursuant to the AL Chemy Loan Agreement the Bank has a security
            interest in all of Industrier's shares in AL Chemy and Wangs Fabrik.
            Industrier is the beneficial owner of all of the shares of AL Chemy
            and Wangs Fabrik. AL Chemy and Wangs Fabrik are the record holders
            of 10,599,459 shares of the Class B Stock beneficially owned by
            Industrier. Therefore, in certain cases upon the occurrence of an
            event of default under the AL Chemy Loan Agreement, the Bank could
            become the beneficial owner 10,599,459 shares of Class B Stock
            beneficially owned by Industrier.

            On September 30, 2002, the Bank provided a letter to Industrier and
            AL Chemy, filed as Exhibit 1 to this Amendment No. 9 to the Schedule
            13D and incorporated herein by reference, in which, among other
            things, the Bank agreed to extend the term of the AL Chemy Loan
            Agreement until November 1, 2002 and to modify the default
            provisions to require the maintenance of certain collateral value
            (which includes a computation based, in part, on the market value of
            the Common Stock). The remaining default provisions are as set forth
            in Section 13.1 of the AL Chemy Loan Agreement filed as Exhibit 1 to



                               Page 4 of 6 Pages

            Amendment No. 6 to the Schedule 13D, the provisions of which are
            incorporated herein by reference.

      (b)   8,226,562 of the shares of Common Stock beneficially owned by
            Industrier are held of record by Wangs Fabrik and 2,372,897 shares
            of Common Stock beneficially owned by Industrier are held of record
            by AL Chemy. However, Industrier possesses the sole power to direct
            voting and disposition of such shares. Sissener beneficially owns
            373,667 shares of Common Stock and he possesses sole power to direct
            voting and disposition of the shares of Common Stock beneficially
            owned by him.

      (c)   Except for the transactions described herein, there have been no
            other transactions in the securities of the Issuer effected by
            Industrier in the last 60 days.

      (d)   No person other than Industrier or its wholly-owned subsidiaries has
            any right to receive or direct the receipt of dividends from, or the
            proceeds from any sale of, the shares of Class B Stock beneficially
            owned by Industrier or the Common Stock issuable upon conversion
            thereof.

      (e)   Inapplicable.

      ITEM 6.  CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
               RESPECT TO SECURITIES OF THE ISSUER.

      Industrier is not a party or otherwise subject to any contract,
arrangement, understanding or relationship with any person relating to any
securities of the Issuer, except:

      (i) A Loan Agreement dated August 13, 2001 by and between AL Chemy and the
Bank filed as Exhibit 1 to Amendment No. 6 to the Schedule 13D, the provisions
of which are incorporated herein by reference;

      (ii) A Letter Agreement dated August 13, 2001 by and among Industrier,
Wangs Fabrik and the Bank filed as Exhibit 2 to Amendment No. 6 to the Schedule
13D, the provisions of which are incorporated herein by reference; and

      (iii) A letter dated September 30, 2002 to Industrier and AL Chemy from
the Bank filed as Exhibit 1 to this Amendment No. 9 to the Schedule 13D, the
provisions of which are incorporated herein by reference.

      ITEM 7.  MATERIAL TO BE FILED AS EXHIBITS.

      Exhibit 1 - Letter dated September 30, 2002 to Industrier and AL Chemy
from the Bank.


                               Page 5 of 6 Pages

                                   SIGNATURES

      After reasonable inquiry and to the best of each of the undersigned's
knowledge and belief, each of the undersigned certify that the information set
forth in this statement is true, complete and correct.

Date:  October 4, 2002

                                       A. L. INDUSTRIER ASA

                                       By:  /s/ Einar W. Sissener
                                           -------------------------
                                           Name: Einar W. Sissener
                                           Its:  Chairman



                               Page 6 of 6 Pages